Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia  by Kane, John M. et al.
Schizophrenia Research 174 (2016) 93–98
Contents lists available at ScienceDirect
Schizophrenia Research
j ourna l homepage: www.e lsev ie r .com/ locate /schresOverview of short- and long-term tolerability and safety of brexpiprazole
in patients with schizophreniaJohn M. Kane a,⁎, Aleksandar Skuban b, Mary Hobart b, John Ouyang b, Emmanuelle Weiller c,
Catherine Weiss b, Christoph U. Correll a
a The Zucker Hillside Hospital, Department of Psychiatry Research, 75–59 263rd Street, Glen Oaks, NY 11004, USA
b Otsuka Pharmaceutical Development and Commercialization Inc., 508 Carnegie Center Drive, 1 University Square Drive, Princeton, NJ 08540, USA
c H. Lundbeck A/S, Ottiliavej 9, 2500, Valby, Copenhagen, Denmark⁎ Corresponding author.
E-mail addresses: JKane2@nshs.edu (J.M. Kane), Aleks
(A. Skuban), Mary.Hobart@otsuka-us.com (M. Hobart), Jo
(J. Ouyang), EMWE@Lundbeck.com (E. Weiller), Catherin
(C. Weiss), ccorrell@nshs.edu (C. U. Correll).
http://dx.doi.org/10.1016/j.schres.2016.04.013
0920-9964/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 22 December 2015
Received in revised form 6 April 2016
Accepted 11 April 2016
Available online 14 May 2016Second-generation antipsychotics have demonstrated efﬁcacy for patients with schizophrenia but are associated
with wide-ranging side effects. Brexpiprazole, a serotonin-dopamine activity modulator, has demonstrated efﬁ-
cacy in adult patients with schizophrenia. This paper provides an overview of the safety and tolerability of
brexpiprazole in patients with schizophrenia through examination of pooled safety data from one Phase 2 and
two Phase 3 6-week, short-term studies, and two open-label, 52-week, long-term studies.
In the short-term studies, there were no reports of treatment-emergent adverse events (TEAEs) with an inci-
dence ≥ 5% and twice that of placebo in patients treated with brexpiprazole 2–4 mg. In the long-term studies,
TEAEs reported by ≥5% of patients were schizophrenia (10.7%), insomnia (8.0%), weight increase (7.7%), head-
ache (6.0%), and agitation (5.2%). Akathisia rates were low in the short- (5.8%, pooled brexpiprazole group)
and long-term studies (4.6%). Sedation rates were low in the short- (2.3%, pooled brexpiprazole group) and
long-term studies (0.9%). Mean body weight increase was 1.1 kg in both short- and long-term studies.
For all studies, changes from baseline to last visit in laboratory parameters, electrocardiogram values, and vital
signs were small and not clinically relevant. Changes in lipid proﬁles or other metabolic parameters were also
small. Collectively, these studies suggest that brexpiprazole was well tolerated, with a favorable safety proﬁle
that does not exhibit signiﬁcant rates of important adverse events that can be seen with existing antipsychotics
(akathisia, sedation, weight gain, or QTc prolongation), and therefore may provide a useful treatment option for
patients with schizophrenia.
ClinicalTrials.gov: NCT00905307; NCT01396421; NCT01393613; NCT01649557; NCT01397786.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Schizophrenia is a life-long, frequently debilitating psychotic illness
of positive (e.g. delusions, hallucinations) and negative (e.g. emotional
withdrawal, passivity) symptoms (Volavka and Citrome, 2009). Addi-
tionally, it is associated with cognitive impairments including memory
problems and attention deﬁcits (Saha et al., 2005; Volavka and
Citrome, 2009). Collectively, these symptoms signiﬁcantly affect social
and occupational functioning and quality of life (Browne et al., 2000;
Hayhurst et al., 2014; Volavka and Citrome, 2009).
Attaining successful schizophrenia treatment outcomes remains chal-
lengingbecause of theheterogeneity of therapeutic and adverse responses
(Citrome, 2013; Correll, 2010; De Hert et al., 2012; Leucht et al., 2013).andar.Skuban@otsuka-us.com
hn.Ouyang@otsuka-us.com
e.Weiss@otsuka-us.com
. This is an open access article underCurrent second-generation antipsychotics are associated with numerous
side effects:weight gain,metabolic abnormalities, hyperprolactinemia, se-
dation, restlessness, akathisia/other extrapyramidal symptoms (EPS), and
QTc prolongation (De Hert et al., 2011; Kane et al., 2010; Leucht et al.,
2013). There remains a need for antipsychoticmedications offering an ap-
propriate balance between efﬁcacy against the core symptoms of schizo-
phrenia and a good safety/tolerability proﬁle, with minimal activating
(e.g. akathisia, insomnia, restlessness, and anxiety) and sedating (e.g. se-
dation, somnolence) adverse events (AEs), and low EPS, metabolic, and
cardiovascular risks (Correll, 2010; De Hert et al., 2011).
Pharmacological proﬁles of current second-generation antipsy-
chotics vary in their afﬁnity for dopamine and serotonin receptor sub-
types and for adrenergic, histaminergic, and muscarinic receptors
(Correll, 2010). Activity at these receptors may contribute to variation
in side-effect proﬁles (Miller, 2004; Sharpley et al., 2005).
Brexpiprazole (OPC-34712) is a serotonin–dopamine activitymodu-
lator that was approved in the USA in July 2015 for the treatment of
schizophrenia and as an adjunctive therapy to antidepressants for thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at
5-HT2A and noradrenergic α1B/2C receptors, all with similar potency
(Maeda et al., 2014a). It has a lower intrinsic activity at the D2 receptor
and stronger antagonism at the 5-HT2A receptor than aripiprazole, the
ﬁrst D2 partial agonist approved for the treatment of schizophrenia
(Maeda et al., 2014a). Partial agonism, with low intrinsic activity at
the D2 receptor in addition to strong 5-HT2A antagonism, may reduce
the potential to induce both D2 agonist-mediated AEs such as akathisia,
insomnia, restlessness, and nausea, and D2 antagonist-like AEs such as
EPS, hyperprolactinemia, and tardive dyskinesia (Kapur et al., 2000;
Laoutidis and Luckhaus, 2014; Maeda et al., 2014a; Maeda et al.,
2014b). Additionally, brexpiprazole has, relative to D2/5-HT1A receptors,
moderate afﬁnity for histamineH1 receptors (Maeda et al., 2014a), often
associated with sedation and weight gain. This unique pharmacological
proﬁle may provide improved tolerability, compared with other agents,
without compromising efﬁcacy.
Results obtained from two Phase 3 short-term studies have demon-
strated efﬁcacy of brexpiprazole as a treatment for acute schizophrenia.
In one trial, treatment with brexpiprazole 2 and 4 mg showed statisti-
cally signiﬁcant improvements from baseline to week 6 in Positive and
Negative Syndrome Scale (PANSS) total score, compared with placebo
(Correll et al., 2015; Kane et al., 2015a). In ameta-analysis of both trials,
both the 2 mg and 4 mg groups showed efﬁcacy vs. placebo (Cohen's d
effect size 0.27 and 0.33) (Correll et al., 2016). This meta-analysis pre-
sents analyses of safety and tolerability data for brexpiprazole in adult
patients with schizophrenia using pooled results from one Phase 2
and two Phase 3 short-term studies, and from two long-term studies.
Pooled efﬁcacy data from the pivotal short-term studies are reported
separately (Correll et al., 2016).
2. Methods
An overview of the Phase 2 and Phase 3 studies included in this
safety analysis is presented in Table 1.
Written informed consent was obtained from all patients. The stud-
ies were conducted in compliance with the International Conference on
Harmonization Good Clinical Practice Consolidated Guideline. The pro-
tocols were approved by independent ethics committees.
2.1. Study design
2.1.1. Short-term studies
The Phase 3 short-term studies were conducted in patients aged
18–65 years with a current diagnosis of schizophrenia as deﬁned byTable 1
Phase 2/3 clinical studies in treatment of adults with acute schizophrenia.
Study Study design and dosage
Short-term, double-blind studies
Flexible dose (Phase 2)
Study 1; NCT00905307; STEP 203 6-week, double-blind, placebo-controll
0.25 mg to 6 mg
Fixed dose (Phase 3)
Study 1; NCT01396421; VECTOR 6-week, double-blind, placebo-controll
and 4 mg ﬁxed dose
Study 2; NCT01393613; BEACON 6-week, double-blind, placebo-controll
4 mg ﬁxed dose
Long-term, open-label studies
Study 1 (Phase 2); NCT01649557; STEP 210 52-week, open-label extension study; ﬂ
Study 2 (Phase 3)b; NCT01397786; ZENITH 52-week, open-label extension; ﬂexibl
a The safety population was composed of all patients who were randomized to treatment an
b Study duration was amended to 26 weeks owing to a sufﬁcient number of patients expose
c As of cut-off date of 15 May 2015, for ongoing studies.
d Only a small number of patients received a brexpiprazole dose N 4 mg. This dose is not bethe Diagnostic and Statistical Manual of Mental Disorders, fourth edition,
Text Revision (DSM-IV-TR) criteria, who would beneﬁt from hospitali-
zation or continued hospitalization for the treatment of a current
acute exacerbation of schizophrenia. Patients were excluded if it was
their ﬁrst episode of schizophrenia or they had a DSM-IV-TR Axis I diag-
nosis other than schizophrenia, clinically signiﬁcant tardive dyskinesia,
substance abuse/dependence in the previous 180 days, or a clinically
signiﬁcant medical condition. Detailed methodology of the Phase 3
studies has been described previously (Correll et al., 2015; Kane et al.,
2015a).
All studiesweremulticenter and conducted at sites inNorth America
(35%), Europe (50%), Asia (5%), and Latin America (10%). These ran-
domized, double-blind, placebo-controlled studies consisted of screen-
ing (≤14 days), double-blind treatment (6 weeks), and safety follow-
up (30 days) phases.
The Phase 2 study included an active reference drug (aripiprazole
10–20 mg) for demonstration of assay sensitivity only.
2.1.2. Long-term studies
The long-term studies were 52-week, ﬂexible-dose, open-label ex-
tension studies that enrolled patients who completed the short-term
studies. The Phase 2 extension study also included de novo patients
who met the short-term study eligibility criteria. Study 1 (1–6 mg
brexpiprazole) has been completed, and Study 2 (1–4 mg
brexpiprazole) is ongoing (Table 1). Dose ranges were chosen to mirror
those of the parent studies.
2.2. Safety assessments
Safety assessments comprised AEs, serious AEs (SAEs), bodyweight,
laboratory parameters, vital signs, electrocardiograms (ECGs),
Simpson–Angus Scale (SAS) (Simpson and Angus, 1970), Barnes
Akathisia Rating Scale (BARS) (Barnes, 1989), Abnormal Involuntary
Movement Scale (AIMS) (Guy, 1976), and Columbia Suicide Severity
Rating Scale (C-SSRS) (Posner et al., 2011). An overview of safety assess-
ment timings can be found in Supplementary Table 1.
2.3. Statistical analysis
All analyses were performed in the safety population, comprising
patients who received at least one dose of study medication.
For the short-term studies, data for brexpiprazole were pooled into
integrated dose groups (b2 mg, 2–4 mg, and N4 mg), plus a pooled
brexpiprazole group. Baseline was deﬁned as the last measurement
prior to the ﬁrst dose of drug received.Number of patients in safety populationa
Brexpiprazole Placebo Aripiprazole
ed study; ﬂexible doses of 314 95 50
ed study; 0.25 mg, 2 mg, 452 184 N/A
ed study; 1 mg, 2 mg, and 490 184 N/A
exible doses of 1 mg to 6 mgd 28 N/A N/A
e doses of 1 mg to 4 mg 1031c N/A N/A
d received ≥ 1 dose of study medication as indicated on the dosing record.
d for N 52 weeks.
ing studied further.
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were pooled. Baseline was deﬁned according to patient cohort and
study. In the open-label study, baseline was the last measurement
prior to starting brexpiprazole. For patients from the short-term studies
entering the long-term safety studies, baselinewas the assessment from
the last scheduled visit of the double-blind study prior to starting
brexpiprazole. For de novo patients for whom cross-titration/washout
was required in Study 2, baseline was the week 4 visit of the screening
and conversion phase.
Changes from baseline to last visit (deﬁned as the last evaluable
assessment at a scheduled visit for all parameters [except body weight,
where last observation carried forward was used]) were calculated for
all studies. Number-needed-to-harm (NNH) estimates for discontinua-
tions due toAEswere calculated as 100divided by absolute risk reduction.
3. Results
3.1. Patient disposition
In the short-term studies, 1256 patients were randomized to
brexpiprazole, 463 to placebo, and 50 to aripiprazole. Overall, treatment
was completed by 65.4% of patients receiving brexpiprazole and 60.5%
of patients receiving placebo. The most frequently reported reasons
for discontinuation were withdrawal of consent (13.9%, vs. 11.9% for
placebo) for the pooled brexpiprazole group and AEs for placebo
(12.7%, vs. 8.1% for pooled brexpiprazole). Mean treatment duration
was similar for brexpiprazole (34.3 days) and placebo (33.0 days).
Mean (SD) dose for the 2–4 mg brexpiprazole group was 2.6 (0.8) mg.
In the long-term studies, 34.0% of patients completed 52 weeks of
treatment; 17.6% were active in long-term Study 2 at time of data cut-
off. Themost frequently reported reasons for discontinuationwere con-
sent withdrawal (16.1%) and AEs (14.5%). At data cut-off, mean (SD)
duration of treatment was 200.0 (136.2) days and total exposure was
584.8 patient years. Mean (SD) dose was 3.1 (1.0) mg.
In the long-term studies, patient distribution by parent study treat-
ment was: prior placebo, 208 (19.6%); prior brexpiprazole, 625
(59.0%); prior aripiprazole, 2 (0.19%); de novo, 224 (21.2%). Patients
who received brexpiprazole in the parent study had the highest inci-
dence of discontinuations because of an AE (16.5%), while patients
who had received placebo had the lowest (11.5%).
3.2. Patient demographics and baseline characteristics
Demographic and baseline characteristics were similar across the
studies (Table 2). In the short-term studies, the mean age was
39.8 years, 62.9% of patients were male, and 63.1% were Caucasian.
The long-term studies were similar: mean age 39.8 years, 60.7% male,
64.0% Caucasian.
In the short-term studies, a similar percentage of patients in each
group (71.0–74.8%) took ≥1 concomitant medication during the study
(Supplementary Table 2). In the long-term studies, 58.1% of patientsTable 2
Summary of demographic and baseline characteristics (safety population).
Assessment Short-term
Brexpiprazole
b 2 mg
(n = 341)
2–4 m
(n =
Age, years, mean (SD) 39.7 (11.0) 38.8 (
Female, n (%) 123 (36.1) 305 (
Caucasian, n (%) 215 (63.0) 517 (
Weight, kg, mean (SD) 77.8 (20.3) 78.5 (
BMI, kg/m2, mean (SD) 26.7 (6.4) 26.8 (
Age at ﬁrst diagnosis, years, mean (SD) 26.7 (8.9) 26.3 (
Duration of current episode, estimated weeks, mean (SD) 2.5 (2.2) 2.6 (
BMI, body mass index; N/A, not applicable; SD, standard deviation.took ≥1 concomitant medication (Supplementary Table 2). Lorazepam
was the most frequently reported rescue medication (47.7% and 44.1%
in the pooled brexpiprazole and placebo groups, respectively, from the
short-term studies; 19.6% from the long-term studies).
3.3. Adverse events
Treatment-emergent adverse events (TEAEs) reported by ≥5% of pa-
tients are displayed in Table 3. Most TEAEsweremild ormoderate in se-
verity, based on investigator assessment.
In the short-term studies of brexpiprazole up to 4mg, no TEAEswith
an incidence ≥ 5% and twice that of placebo were reported. Overall, the
incidence of akathisia was generally low (5.8% vs. 4.5% for the pooled
brexpiprazole and placebo groups, respectively) and increased with
doses N 4 mg (15.1%); this observation, which was in the Phase 2
study, was the primary reason why doses N 4 mg were not tested in
Phase 3. Sedation TEAEs were reported by 2.3% of patients in both the
brexpiprazole 2–4 mg and pooled brexpiprazole groups, and 0.6% in
the placebo group. Somnolence TEAEs were reported by 2.6% and 2.5%
in the brexpiprazole 2–4 mg and pooled brexpiprazole groups, respec-
tively, and 2.6% in the placebo group. The NNH estimates for akathisia,
sedation, and weight gain in the short-term studies were 84, 60 (seda-
tion rates were 2.3% for the brexpiprazole 2–4 mg group vs. 0.6% for
the placebo group), and 40, respectively, for the brexpiprazole 2–4 mg
group. The most frequently reported SAEs were associated with under-
lying disease; schizophrenia (1.2% and 2.4%, respectively) and psychotic
disorder (0.6% and 0.9%, respectively).
In the long-term studies, 58.6% of patients reported ≥1 TEAE, themost
frequent being insomnia and schizophrenia (Table 3). Sedation and som-
nolence TEAEs were reported by 0.9% and 2.4% of patients, respectively.
The most frequently reported SAEs were associated with underlying dis-
ease, including schizophrenia (7.9%) and psychotic disorder (1.3%).
There were six deaths overall: one in the short-term controlled
study (cause of death not speciﬁed) and ﬁve in the completed long-
term study (peritonitis, septic shock, cardiac failure, coronary artery dis-
ease, and completed suicide). In the short-term studies, 30 (8.8%), 61
(7.4%), 11 (11.8%), 102 (8.1%), and 59 (12.7%) patients in the b 2 mg,
2–4mg, N 4mg, pooled brexpiprazole, and placebo groups, respectively,
discontinued because of an AE, as did 154 patients (14.5%) in the long-
term studies. Most subjects with AEs resulting in discontinuation had
events in the psychiatric disorders system organ class.
3.4. Extrapyramidal-symptoms-associated adverse events
Across all studies, themajority of EPS-associated TEAEsweremild or
moderate in severity, based on investigator assessment. In the short-
term studies, EPS-associated TEAEs (Supplementary Table 3) did not in-
dicate dose-related tolerability issues. Four patients discontinued be-
cause of an EPS-related TEAE (three from the pooled brexpiprazole
group [severe psychomotor hyperactivity (brexpiprazole 4 mg group),
tremor and akathisia (both brexpiprazole 5.0 ± 1.0 mg group)] andLong-term
g
822)
N 4 mg
(n = 93)
Pooled
(n = 1256)
Placebo
(n = 463)
Brexpiprazole
(1–6 mg)
(n = 1059)
10.8) 39.5 (11.1) 39.1 (10.9) 39.4 (10.9) 39.8 (11.1)
37.1) 38 (40.9) 466 (37.1) 176 (38.0) 416 (39.3)
62.9) 60 (64.5) 792 (63.1) 291 (62.9) 678 (64.0)
19.5) 72.1 (18.4) 77.8 (19.7) 77.4 (18.4) 81.2 (21.0)
6.0) 25.3 (6.3) 26.7 (6.2) 26.5 (5.5) 27.8 (6.6)
8.4) 26.9 (9.6) 26.5 (8.6) 26.3 (8.9) N/A
2.4) 2.3 (1.6) 2.5 (2.3) 2.7 (2.8) N/A
Table 3
Summary of adverse events (safety population).
Short-term Long-term
Brexpiprazole
b 2 mg
(n = 341)
2–4 mg
(n = 822)
N 4 mg
(n = 93)
Pooled
(n = 1256)
Placebo
(n = 463)
Brexpiprazole
(1–6 mg)
(n = 1059)
Any TEAE, n (%) 204 (59.8) 487 (59.2) 70 (75.3) 761 (60.6) 283 (61.1) 621 (58.6)
Death, n (%) 0 (0.0) 0 (0.0) 1 (1.1) 1 (0.1) 0 (0.0) 5 (0.5)
Any SAE, n (%) 10 (2.9) 19 (2.3) 4 (4.3) 33 (2.6) 20 (4.3) 126 (11.9)
Any AE leading to discontinuation of study drug, n (%) 30 (8.8) 61 (7.4) 11 (11.8) 102 (8.1) 59 (12.7) 147 (13.9)
Incidence of TEAEs reported by ≥5% patients in any group
Insomnia, n (%) 39 (11.4) 93 (11.3) 9 (9.7) 141 (11.2) 61 (13.2) 85 (8.0)
Headache, n (%) 32 (9.4) 91 (11.1) 7 (7.5) 130 (10.4) 52 (11.2) 64 (6.0)
Agitation, n (%) 22 (6.5) 57 (6.9) 7 (7.5) 86 (6.8) 36 (7.8) 55 (5.2)
Akathisia, n (%) 12 (3.5) 47 (5.7) 14 (15.1) 73 (5.8) 21 (4.5) 49 (4.6)
Schizophrenia, n (%) 16 (4.7) 41 (5.0) 3 (3.2) 60 (4.8) 43 (9.3) 113 (10.7)
Weight gain, n (%) 15 (4.4) 38 (4.6) 6 (6.5) 59 (4.7) 9 (1.9) 82 (7.7)
Constipation, n (%) 12 (3.5) 33 (4.0) 6 (6.5) 51 (4.1) 24 (5.2) 8 (0.8)
Nausea, n (%) 8 (2.3) 30 (3.6) 6 (6.5) 44 (3.5) 16 (3.5) 17 (1.6)
Anxiety, n (%) 13 (3.8) 15 (1.8) 10 (10.8) 38 (3.0) 14 (3.0) 22 (2.1)
Somnolence, n (%) 5 (1.5) 21 (2.6) 5 (5.4) 31 (2.5) 12 (2.6) 25 (2.4)
Dizziness, n (%) 8 (2.3) 16 (1.9) 5 (5.4) 29 (2.3) 8 (1.7) 13 (1.2)
Blood CPK increased, n (%) 6 (1.8) 17 (2.1) 5 (5.4) 28 (2.2) 5 (1.1) 13 (1.2)
Extrapyramidal disorder, n (%) 4 (1.2) 15 (1.8) 6 (6.5) 25 (2.0) 10 (2.2) 14 (1.3)
AE, adverse event; CPK, creatine phosphokinase; EPS, extrapyramidal symptoms; SAE, serious adverse event; TEAE, treatment-emergent adverse event.
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because of an EPS-related TEAE (four with akathisia [two prior
brexpiprazole, one de novo, one prior placebo], one with severe tremor
[prior brexpiprazole], onewith parkinsonism [prior brexpiprazole], one
with dyskinesia [de novo], and one with muscle rigidity [prior
brexpiprazole]).
In the long-term studies, 9.3% of patients reported an EPS-related
TEAE (Supplementary Table 3). The incidence of EPS-related TEAEs
was higher in the prior placebo (13.0%) and de novo groups (11.2%)
than in the prior brexpiprazole group (7.4%).
Incidence of akathisia was similar in the brexpiprazole 2–4 mg,
pooled brexpiprazole, and placebo groups in the short-term studies
and the brexpiprazole group in the long-term studies. Akathisia
occurred early during treatment (peak incidence between days 8 and
11 of treatment), coincided with treatment initiation, and was related
to dose and dose increases. Discontinuation rates for akathisia were
b1% in both short-term (0.1%) and long-term (0.4%) studies. There
were no reports of tardive dyskinesia in brexpiprazole-treated patients
in any of the studies. One patient (de novo) in the long-term studies
discontinued because of dyskinesia.
There were minimal changes from baseline to last visit in all SAS,
BARS, and AIMSmean scores for all studies, and no dose-related tolera-
bility issues in the short-term studies (Supplementary Table 4).3.5. Body weight
In the short-term (6-week) studies, mean increase in body weight
was 1.1 kg and 0.2 kg in the pooled brexpiprazole and placebo groups,
respectively. Overall, 10.4% in the brexpiprazole 2–4 mg group, 9.9% in
the pooled brexpiprazole group, and 4.8% in the placebo group had
clinically relevant weight increases (≥7%). No patients discontinued
because of a TEAE associated with weight gain.
In the long-term studies, the overall mean increase in body weight
was 1.1 kg for brexpiprazole treated patients. For patients exposed for
≥52 weeks the mean increase in body weight was 2.2 kg. Overall, 18.2%
of patients had ≥7% weight increase. A total of 7.8% of patients reported
a TEAE associated with weight increase, and 0.5% discontinued for this
reason. For patients exposed for ≥52 weeks, 5.6% gained ≥15 kg. Patients
whohadbeen exposed to brexpiprazole in a parent studyhadmore stable
meanweight and less weight gain over time than patients previously ex-
posed to placebo (Supplementary Fig. 1).3.6. Metabolic parameters
Mean changes from baseline to last visit in all metabolic parameters
were similar for all studies (Table 4). A detailed description of shifts in
fasting lipids and glucose in the short- and long-term studies can be
found in Supplementary Table 5.
The incidence of new diagnosis ofmetabolic syndromewas 1.2% and
0.8% in the pooled brexpiprazole and placebo groups, respectively, in
the short-term studies, and 3.1% in the long-term studies. Metabolic
syndrome was recorded for 7 of the 213 patients treated with
brexpiprazole for ≥52 weeks.3.7. Prolactin
Prolactin changes were small and similar across all studies (Table 4).
TEAEs potentially related to prolactin were mild or moderate, based on
investigator assessment, and were reported in six patients (0.5%) in the
brexpiprazole-treated groups and two (0.4%) in the placebo group. In all
the brexpiprazole groups, 18 women (5.5%) and 15 men (2.7%) had an
elevation N2× upper limit of normal (ULN), and 3 (0.9%) women and
5 men (0.9%) had N3× ULN, reported at one visit. All were
asymptomatic.
In the long-term studies, mean changes in prolactin levels from
baseline were not clinically meaningful. TEAEs related to prolactin
were reported in ﬁve patients (0.5%); one had their dose reduced, and
none discontinued. Overall, 40 female (10.2%) and 38 male (6.3%)
patients had a post-baseline value N 2× ULN, including 21 female
(5.4%) and 14 male (2.3%) patients with a post-baseline value N 3× ULN.
No patients discontinued because of hyperprolactinemia.3.8. Other measures
In the short-term studies, mean (SD) change from baseline in crea-
tine phosphokinase (CPK) showed an increase of 72.81 (534.38) U/L
and 65.28 (1213.54) U/L in the pooled brexpiprazole and placebo
groups, respectively. In the brexpiprazole groups, three patients had a
TEAE of rhabdomyolysis; all were SAEs and two patients discontinued.
However, classiﬁcation of rhabdomyolysis was based on blood CPK
levels only. Other than the increased CPK levels, no patient had symp-
toms characteristic of rhabdomyolysis.
Table 4
Mean change (SD) in fasting metabolic parameters and prolactin from baseline to last visit (safety population).
Assessment Short-term Long-term
Brexpiprazole
b 2 mg
(n = 341)
2–4 mg
(n = 822)
N 4 mg
(n = 93)
Pooled
(n = 1256)
Placebo
(n = 463)
Brexpiprazole
(1–6 mg)
(n = 1059)
Fasting metabolic parameters
Cholesterol, mg/dL −3.75 (29.44)
(n = 311)
2.26 (29.88)
(n = 752)
−6.52 (31.61)
(n = 88)
−0.03 (30.04)
(n = 1151)
−3.48 (29.39)
(n = 415)
0.24 (33.50)
(n = 939)
HDL cholesterol, mg/dL −0.98 (12.34)
(n = 185)
1.15 (9.93)
(n = 752)
0.08 (8.51)
(n = 88)
0.49 (10.57)
(n = 1151)
−1.55 (8.62)
(n = 415)
0.47 (11.31)
(n = 939)
LDL cholesterol mg/dL −0.29 (26.26)
(n = 311)
1.33 (24.96)
(n = 660)
−24.50 (16.26)
(n = 2)
0.91 (25.25)
(n = 847)
−1.82 (25.64)
(n = 325)
−0.53 (28.13)
(n = 900)
Triglycerides, mg/dL −5.84 (71.41)
(n = 311)
0.06 (76.21)
(n = 752)
−2.90 (75.92)
(n = 88)
−1.76 (74.90)
(n = 1151)
−3.34 (64.27)
(n = 415)
1.66 (72.85)
(n = 939)
Glucose, mg/dL 1.38 (16.38)
(n = 308)
1.09 (15.92)
(n = 748)
3.69 (14.07)
(n = 88)
1.37 (15.91)
(n = 1144)
0.46 (14.49)
(n = 414)
2.59 (21.62)
(n = 936)
HbA1C, % −0.00 (0.29)
(n = 280)
0.02 (0.33)
(n = 730)
0.03 (0.25)
(n = 73)
0.01 (0.31)
(n = 1083)
0.01 (0.31)
(n = 388)
0.06 (0.44)
(n = 996)
Prolactin
Females, ng/mL −7.24 (36.45)
(n = 117)
−1.21 (27.14)
(n = 291)
−10.30 (44.80)
(n = 37)
−3.55 (31.65)
(n = 445)
−10.54 (36.80)
(n = 164)
2.78 (0.50)
(n = 392)
Males, ng/mL −3.01 (13.26)
(n = 210)
−1.16 (10.25)
(n = 488)
−3.54 (11.87)
(n = 55)
−1.85 (11.31)
(n = 753)
−1.60 (9.94)
(n = 262)
0.60 (0.09)
(n = 607)
HbA1C, hemoglobin A1C; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD, standard deviation.
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CPK was −5.97 U/L (852.82). No patient developed rhabdomyoly-
sis. Changes from baseline to last visit in laboratory/ECG parame-
ters (Supplementary Table 6) and vital signs were negligible for
all studies. No dose-related tolerability issues were apparent in
the short-term studies.
3.9. Suicidality
The incidence of TEAEs associated with suicidality was low. In the
short-term studies, three patients (0.2%) in the pooled brexpiprazole
group and one (0.2%) in the placebo group reported a TEAE related to
suicidality. None discontinued. Treatment-emergent suicidal behavior
as assessed by C-SSRS was reported by two patients (2 mg
brexpiprazole group and placebo group).
In the long-term studies, eight patients (0.8%) reported a TEAE
related to suicidality: six patients reported suicidal ideation, one
attempted suicide, and one completed suicide. C-SSRS assessment iden-
tiﬁed two patients (0.19%) with treatment-emergent suicidal behavior.
4. Discussion
Results from these ﬁve studies in patients with schizophrenia suggest
that brexpiprazole 2–4 mg is well tolerated, as conﬁrmed by relatively
high completion rates in the short-termstudies and lowTEAE-related dis-
continuation rates across all studies. The incidence of SAEs and discontin-
uations because of TEAEs were higher for placebo than brexpiprazole in
the short-term studies; most were indicative of worsening schizophrenia
symptoms. For all studies, therewere low rates of activating and sedating
AEs in brexpiprazole-treated patients, conﬁrming the pharmacology-
predicted safety proﬁle of brexpiprazole.
Akathisia is a common side effect of some antipsychotic treatments
(Kane et al., 2009; Kane et al., 2015b; Rummel-Kluge et al., 2012);
brexpiprazole possesses a pharmacological binding proﬁle that provides
low intrinsic activity at D2 receptors alongside strong antagonistic activity
at 5-HT2A receptors, which may minimize akathisia and other activating
side effects (Kapur et al., 2000; Laoutidis and Luckhaus, 2014; Maeda
et al., 2014a). In the short-term studies, akathisia was reported at a
slightly higher incidence in patients treated with brexpiprazole (5.8%
[pooled brexpiprazole group]) and placebo (4.5%), with only one patient,
in the N 4 mg group, discontinuing. The long-term studies support thispromising tolerability proﬁle: b1% patients discontinued because of
akathisia, and there was a relatively low incidence of EPS-related TEAEs
(predominantly in the prior placebo and de novo groups).
Sedation and somnolence rates were low for both short- and long-
term studies, with no events leading to discontinuation.
Antipsychotic medications are associated with increases in body
weight (De Hert et al., 2011; De Hert et al., 2012; Leucht et al., 2013). In
this analysis, changes in body weight were moderate for all groups in the
short-term studies and not markedly different between studies. Our re-
sults showed that more patients had clinically relevant weight gain
(≥7%) following long-term (18.2%) compared with short-term (9.9%)
treatment, and that patients exposed to brexpiprazole in a parent study
tended tohave lessweight gainover timecomparedwithpatients exposed
to placebo. Although comparisonswith other studies should bemadewith
caution, clinically signiﬁcantweight gain in long-term studies has been ob-
served in 10–14% of patients taking aripiprazole (Chrzanowski et al., 2006;
McQuade et al., 2004) and 37% taking quetiapine (Brecher et al., 2007).
For the short-term studies, NNH estimates were calculated for the
2–4 mg brexpiprazole group, a dose range with demonstrated efﬁcacy
in acute schizophrenia (Correll et al., 2015; Kane et al., 2015a). The high
NNH values for akathisia (84), sedation (60), and weight gain ≥7% (40)
are encouraging as previous studies have reported NNH values for
akathisia of 34, 15, and 25 for aripiprazole, risperidone, and olanzapine,
respectively (Belgamwar andEl-Sayeh, 2011; Citrome, 2013), NNHvalues
for sedation of 23, 20, and 3 for aripiprazole, risperidone, and quetiapine,
respectively (Belgamwar and El-Sayeh, 2011; Komossa et al., 2010), and
NNH values forweight gain ≥7% of 20, 12, 6, and 6 for aripiprazole, risper-
idone, olanzapine, and quetiapine, respectively (Citrome, 2013; De Hert
et al., 2012).
Metabolic side effects, such as hyperglycemia, dyslipidemia, and
metabolic syndrome, have been associated with second-generation
antipsychotics (e.g. olanzapine and quetiapine) (De Hert et al., 2011;
De Hert et al., 2012). However, we observed only small changes in
metabolic parameters in brexpiprazole-treated patients across the
studies and only one case of metabolic syndrome, suggesting that
brexpiprazole has a good metabolic proﬁle. No clinically signiﬁcant
differences between brexpiprazole and placebo were observed for
other safety and tolerability parameters, and no new safety issues
associated with long-term use were identiﬁed.
With current second-generation antipsychotics being associated
with an array of side effects, there is a need for efﬁcacious antipsychotics
98 J.M. Kane et al. / Schizophrenia Research 174 (2016) 93–98with a more favorable safety proﬁle. Based on the current analyses,
brexpiprazole appears to be a suitable treatment for patients with
schizophrenia, with good overall tolerability in both short- and long-
term settings. Together with the demonstrated efﬁcacy (Correll et al.,
2016), the favorable long-term tolerability proﬁle provides reason to
anticipate that brexpiprazole will provide a valuable therapeutic option
for treating patients with schizophrenia.
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